Microcap Ledger Scynexis Inc $SCYX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Jersey City, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 9,949,609 [10-Q 2026-08-10]
What the company doesAI summary of filing
SCYNEXIS is a clinical-stage biopharmaceutical company developing antifungal drugs to treat fungal infections. The company has one FDA-approved product, ibrexafungerp (BREXAFEMME), which was approved in 2021-2022 for vulvovaginal candidiasis and is licensed to GlaxoSmithKline; ibrexafungerp generates limited revenue for the company through milestone payments and royalties. The company's lead development candidate, SCY-247, is a second-generation antifungal in Phase 1 clinical trials, with additional compounds in earlier development stages. The company is pre-revenue from product sales and depends on milestone payments, royalties, and capital raising to fund operations. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $235.0K | −$13.90M | −$22.99M | $10.49M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $20.60M | −$8.61M | −$5.28M | $21.26M | [10-K 2026-03-04] |
| FY ended Dec 2024 | $3.75M | −$21.29M | −$24.01M | $16.05M | [10-K 2026-03-04] |
- Quarterly cash burn
- −$11.49M
- Cash runway Estimate
- ~2.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 37,948,991 | [10-Q 2024-11-06] |
| 2025-03-01 | 38,981,064 | [10-K 2025-03-12] |
| 2025-05-01 | 39,020,274 | [10-Q 2025-05-15] |
| 2025-08-08 | 41,924,941 | [10-Q 2025-08-13] |
| 2025-11-01 | 41,965,058 | [10-Q 2025-11-05] |
| 2026-03-01 | 44,663,832 | [10-K 2026-03-04] |
| 2026-05-01 | 79,442,633 | [10-Q 2026-05-11] |
| 2026-08-01 | 9,949,609 | [10-Q 2026-08-10] |
- Shelf registration
- S-3 filed 2026-05-01; declared effective 2026-05-08 [S-3 2026-05-01]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-06-26. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-06-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-06-26] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-18 | Burke Steven Keith | grant | 5,750 | — | [4 2026-09-22] |
| 2026-06-26 | Tinmouth Brian Philippe | grant | 2,875 | — | [4 2026-06-30] |
| 2026-06-26 | Macdonald Guy | grant | 2,875 | — | [4 2026-06-30] |
| 2026-06-26 | Anido Armando | grant | 2,875 | — | [4 2026-06-30] |
| 2026-06-26 | Hastings David C | grant | 2,875 | — | [4 2026-06-30] |
| 2026-06-26 | Hanham Ann | grant | 2,875 | — | [4 2026-06-30] |
| 2026-04-01 | Angulo Gonzalez David | buy | 108,695 | — | [4 2026-04-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-22 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-09-10 | 8-K | Director or officer change; Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-07-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-08 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-26 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results; Other events |
| 2026-05-29 | 8-K | Charter, bylaws or fiscal year change |
| 2026-05-22 | 8-K | Shareholder vote results; Other events |
Alerts for $SCYX
Email me when Scynexis Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.